Replacement BAXJECT II / BAXJECT II Hi-Flow Reconstitution Devices co-packaged with Advate/Feiba/Rixubis

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Active substance
  • octocog alfa
  • Factor VIII Inhibitor Bypassing Activity
  • nonacog gamma
Regulatory outcome
Variation
DHPC type
Quality defect
Dissemination date
14/08/2023

Related content

How useful was this page?

Add your rating